Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,900 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 2,900 shares of the stock in a transaction on Monday, January 12th. The stock was acquired at an average price of $27.54 per share, with a total value of $79,866.00. Following the completion of the acquisition, the chief executive officer owned 5,602,302 shares of the company’s stock, valued at $154,287,397.08. This represents a 0.05% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Wednesday, December 31st, Snehal Patel acquired 4,300 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $21.36 per share, with a total value of $91,848.00.
• On Tuesday, December 30th, Snehal Patel acquired 2,900 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $21.73 per share, with a total value of $63,017.00.
• On Thursday, December 18th, Snehal Patel bought 4,100 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $12.62 per share, for a total transaction of $51,742.00.
• On Tuesday, November 25th, Snehal Patel purchased 4,600 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $8.37 per share, with a total value of $38,502.00.
• On Friday, November 7th, Snehal Patel purchased 10,600 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $8.43 per share, with a total value of $89,358.00.
• On Friday, October 31st, Snehal Patel acquired 2,300 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $9.26 per share, for a total transaction of $21,298.00.

Greenwich LifeSciences Price Performance

Shares of GLSI opened at $29.29 on Thursday. Greenwich LifeSciences, Inc. has a one year low of $7.78 and a one year high of $32.91. The company has a market cap of $405.67 million, a PE ratio of -20.06 and a beta of 1.47. The stock has a 50-day moving average of $13.66 and a 200-day moving average of $11.83.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.30). Analysts expect that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on GLSI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Finally, HC Wainwright lifted their price target on Greenwich LifeSciences from $39.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 30th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Greenwich LifeSciences presently has an average rating of “Hold” and a consensus target price of $47.50.

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after purchasing an additional 1,322 shares during the last quarter. Strs Ohio purchased a new position in shares of Greenwich LifeSciences in the 1st quarter worth approximately $177,000. Rhumbline Advisers boosted its stake in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Greenwich LifeSciences by 1.4% in the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after acquiring an additional 1,972 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Greenwich LifeSciences during the second quarter valued at approximately $25,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.